On November 15, 2018, the 69th participant officially enrolled in our ongoing Phase 1 study of the psychological effects of MDMA when used in a therapeutic setting by healthy volunteers. Enrollment in …
From September 26-October 3, 2018, Annie Mithoefer, B.S.N., and Michael Mithoefer, M.D., led a weeklong in-person training in the Netherlands focused on MDMA-assisted psychotherapy in the treatment of …
In the coming year, MAPS plans to apply for a special U.S. Food and Drug Administration (FDA) program called Expanded Access (EA), which allows the use of an investigational medical product (one that has …
From July 16 – 19, 2018, MAPS-sponsored researchers Dr. Michael Mithoefer and Annie Mithoefer, BSN, Marcela Ot’alora, LPC, and Bruce Poulter, RN, together with MAPS Executive Director Rick …
From June 24-30, 2018, Annie Mithoefer, B.S.N. and Michael Mithoefer, M.D., led a weeklong in-person training in Northern California focused on MDMA-assisted psychotherapy in the treatment of posttraumatic …
On July 10, 2018, the 66th participant officially enrolled in our ongoing Phase 1 study of the psychological effects of MDMA when used in a therapeutic setting by healthy volunteers. Enrollment in this …
In preparation for Phase 3 trials starting Summer 2018, the MDMA Therapy Training Program is currently supporting 82 researchers in their final stage of training through our supervision program, a process …
On June 5, 2018, the 65th participant officially enrolled in our ongoing Phase 1 study of the psychological effects of MDMA when used in a therapeutic setting by healthy volunteers. Enrollment in this …
The MDMA Therapy Training Program is currently preparing researchers to work on Phase 3 clinical trials researching MDMA-assisted psychotherapy for Posttraumatic Stress Disorder (PTSD). These 82 therapists …
On May 8, 2018, the 60th participant enrolled in our ongoing Phase 1 study of the psychological effects of MDMA when used in a therapeutic setting by healthy volunteers. Enrollment in this multi-site study …
The MDMA Therapy Training Program, operated by the MAPS Public Benefit Corporation (MPBC), is currently supporting the final segment of training for Phase 3 therapy teams, eighty-two researchers who will …
On April 3, 2018, the 56th participant enrolled in our ongoing Phase 1 study of the psychological effects of MDMA when used in a therapeutic setting by healthy volunteers. Enrollment in this multi-site …
